Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Bevacizumab Replacing Cisplatin in Locally Advanced Nasopharyngeal Carcinoma
NCT05341193Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2022
- Primary completion
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab, bevacizumab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
toripalimabbevacizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05341193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05341193.